Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Antibodies targeting a tumor antigen, GD2, show some efficacy for neuroblastoma but induce severe neuropathic pain and peripheral neuropathy. Here the authors design a gated chimeric antigen receptor (CAR), using GD2 as the gate and another tumor antigen, B7H3, as the target, to find this GD2-B7H3 C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Hamid Bassiri, Michael D. Hogarty, David M. Barrett, Hiroyuki Shimada, Shahab Asgharzadeh
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/92c07d10ceed4a499ccaa1bcf1c46793
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92c07d10ceed4a499ccaa1bcf1c46793
record_format	dspace
spelling	oai:doaj.org-article:92c07d10ceed4a499ccaa1bcf1c467932021-12-02T14:19:11ZPreclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma10.1038/s41467-020-20785-x2041-1723https://doaj.org/article/92c07d10ceed4a499ccaa1bcf1c467932021-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-20785-xhttps://doaj.org/toc/2041-1723Antibodies targeting a tumor antigen, GD2, show some efficacy for neuroblastoma but induce severe neuropathic pain and peripheral neuropathy. Here the authors design a gated chimeric antigen receptor (CAR), using GD2 as the gate and another tumor antigen, B7H3, as the target, to find this GD2-B7H3 CAR capable of suppressing neuroblastoma in mouse models with little adverse effects.Babak MoghimiSakunthala MuthugounderSamy JambonRachelle TibbettsLong HungHamid BassiriMichael D. HogartyDavid M. BarrettHiroyuki ShimadaShahab AsgharzadehNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Babak Moghimi Sakunthala Muthugounder Samy Jambon Rachelle Tibbetts Long Hung Hamid Bassiri Michael D. Hogarty David M. Barrett Hiroyuki Shimada Shahab Asgharzadeh Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
description	Antibodies targeting a tumor antigen, GD2, show some efficacy for neuroblastoma but induce severe neuropathic pain and peripheral neuropathy. Here the authors design a gated chimeric antigen receptor (CAR), using GD2 as the gate and another tumor antigen, B7H3, as the target, to find this GD2-B7H3 CAR capable of suppressing neuroblastoma in mouse models with little adverse effects.
format	article
author	Babak Moghimi Sakunthala Muthugounder Samy Jambon Rachelle Tibbetts Long Hung Hamid Bassiri Michael D. Hogarty David M. Barrett Hiroyuki Shimada Shahab Asgharzadeh
author_facet	Babak Moghimi Sakunthala Muthugounder Samy Jambon Rachelle Tibbetts Long Hung Hamid Bassiri Michael D. Hogarty David M. Barrett Hiroyuki Shimada Shahab Asgharzadeh
author_sort	Babak Moghimi
title	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
title_short	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
title_full	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
title_fullStr	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
title_full_unstemmed	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
title_sort	preclinical assessment of the efficacy and specificity of gd2-b7h3 synnotch car-t in metastatic neuroblastoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/92c07d10ceed4a499ccaa1bcf1c46793
work_keys_str_mv	AT babakmoghimi preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT sakunthalamuthugounder preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT samyjambon preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT rachelletibbetts preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT longhung preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT hamidbassiri preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT michaeldhogarty preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT davidmbarrett preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT hiroyukishimada preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma AT shahabasgharzadeh preclinicalassessmentoftheefficacyandspecificityofgd2b7h3synnotchcartinmetastaticneuroblastoma
_version_	1718391619706683392

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Ejemplares similares